First design
Site theme
Sign up or log in to sign up for discussions!
The Trump administration has pledged to spend $1.950 million on a hundred million doses of a possible COVID-19 vaccine developed through Germany’s BioNTech and US pharmaceutical giant Pfizer, which will be distributed at no fees to U.S. citizens.
BioNTech announced Wednesday that the agreement signed through the White House also includes the option for the U.S. government to purchase an additional 500 million doses, a theme for regulatory approval of the vaccine.
Several governments have signed agreements with some of the 24 teams recently, a human coronavirus vaccine, adding a promising candidate developed through oxford University and AstraZeneca, however, other buyers have refused to disclose the value paid according to the dose.
Since BioNTech candidate vaccines will likely require at least two vaccine-compatible doses, the vaccination fee is approximately $40.
Prices for early procurement agreements vary significantly depending on what is in the agreement and, in particular, the degree to which the government commits to assist in corporate conduct testing and accentuate manufacturing.
U.S. government Operation Warp Speed It aims to supply three hundred million doses of a qualified vaccine through January 2021. He has already spent more than $1 billion on investments in vaccines developed through Moderna and Johnson and Johnson.
In May, the United States won three hundred million doses of the Oxford University and AstraZeneca vaccine for $1 billion.
Earlier this month, BioNTech and Pfizer published initial knowledge of their U.S. clinical trial. They found that two dozen patients who had been injected with the vaccine candidate had developed immune or greater responses than those discovered in recovered coronavirus patients.
Corporations expect approval from the U.S. Food and Drug Administration. From October, after a large-scale trial with 30,000 participants. They say they have the capacity to manufacture 1.4 billion doses by the end of 2021, adding up to a hundred million this year.
“We took the early resolution of starting clinical paints and large-scale production at our own risk to make sure the product would be available without delay if our clinical trials were successful,” said Albert Bourla, Pfizer’s chief executive.
The U.S. resolution It occurs after the BRITISH government ordered 30 million doses of the BioNTech vaccine and 60 million doses of vaccine in Valneva, France, which is less complex in clinical development. But it did not reveal the main monetary points of the agreements.
Kate Bingham, director of the UK government’s vaccine management group, said the country is targeting a total of at least 8 contracts, two for each of the 4 most important vaccine technologies (genetic vaccines, viral vectors, inactivated total viruses and protein-based vaccines. ).
“Initially, we talked to the government about expanding up to 12 vaccines, but chances are about eight, at least initially,” Bingham said. “This would give us a broad and diversified portfolio.”
Ugur Sahin, co-founder and CEO of BioNTech, said, “We are also in complex talks with various government agencies and look forward to announcing new procurement agreements soon.”
BioNTech said it had also expressed interest in offering the COVAX program, which aims to provide a vaccine fairly. It is controlled through Gavi, the Coalition for Epidemic Preparedness Innovations (Cepi) and the World Health Organization.
The Mainz-based company is one of many generations of messenger RNA (mRNA) to expand a COVID-19 vaccine, a faster procedure than classic methods. However, there is still no qualified mNR product on the market.
© 2020 The Financial Times Ltd. All rights reserved. Be redistributed, copied or changed in some way.
Join the Ars Orbital Transmission email for weekly updates in your inbox.